Robotergestützte minimalinvasive Chirurgie bei Hirnstammblutungen (RAINBOW-BSH)
Forschung zu minimalinvasiven chirurgischen Strategien für Hirnstammblutungen mithilfe von Robotik
The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are:
- Establish a multi-center clinical database for brainstem hemorrhage.
- Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits.
- Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning.
Participants in the experimental group will:
- Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture
- Receive conservative non-surgical treatment.
If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Yanbing Yu, M.D.
- Telefonnummer: +86-13901114963
- E-Mail: yuyanbing123@126.com
Studieren Sie die Kontaktsicherung
- Name: Yulian Zhang, M.D.
- Telefonnummer: +86-13051581507
- E-Mail: 398824625@qq.com
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100029
- Rekrutierung
- China-Japan Friendship Hospital
-
Kontakt:
- Yulian Zhang, M.D.
- Telefonnummer: +86-13051581507
- E-Mail: 398824625@qq.com
-
Kontakt:
- Yanbing Yu, M.D.
- Telefonnummer: 13901114963
- E-Mail: yuyanbing123@126.com
-
Unterermittler:
- Xu Yang, M.D.
-
Beijing, Beijing Municipality, China, 100049
- Rekrutierung
- Aerospace Center Hospital
-
Kontakt:
- Feng Yin, M.D.
- Telefonnummer: +86-13381207600
- E-Mail: yinf897@163.com
-
Kontakt:
- Hui Chen, M.D.
- Telefonnummer: +86-13810520648
- E-Mail: 16564583@qq.com
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Rekrutierung
- The First Affiliated Hospital of Guangxi Medical University
-
Kontakt:
- DAQIN FENG
- Telefonnummer: +8619914884494
- E-Mail: 13807713918@163.com
-
-
Hebei
-
Shijiazhuang, Hebei, China, 100190
- Rekrutierung
- Hebei Provincial People's Hospital
-
Kontakt:
- Tao Qian, M.D.
- Telefonnummer: +86-15931423666
- E-Mail: qt1966a@163.com
-
Kontakt:
- Yang Li, M.D.
- Telefonnummer: +86-18632109423
- E-Mail: 772355464@qq.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Rekrutierung
- Nanjing Drum Tower Hospital
-
Kontakt:
- CHUNHUA HANG
- Telefonnummer: +8613813379309
- E-Mail: hang1965@nju.edu.cn
-
Nantong, Jiangsu, China, 226001
- Rekrutierung
- Affiliated Hospital of Nantong University
-
Kontakt:
- JIANHONG SHEN
- Telefonnummer: +8613506287516
- E-Mail: tysjh@163.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Rekrutierung
- The Second Affiliated Hospital of Nanchang University
-
Kontakt:
- HUA GUO
- Telefonnummer: +8613697081718
- E-Mail: ndefy02014@ncu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Rekrutierung
- Huashan Hospital Fudan University
-
Kontakt:
- JIN HU
- Telefonnummer: +8618930174565
- E-Mail: hujin@fudan.edu.cn
-
Shanghai, Shanghai Municipality, China, 201199
- Rekrutierung
- Shanghai Minhang District Central Hospital
-
Kontakt:
- FULIN XU
- Telefonnummer: +8618121270156
- E-Mail: 18918169183@163.com
-
Shanghai, Shanghai Municipality, China, 200120
- Rekrutierung
- Shanghai East Hospital, Tongji University
-
Kontakt:
- CHUNLONG ZHONG
- Telefonnummer: +8613917920669
- E-Mail: drchunlongzhong@tongji.edu.cn
-
Shanghai, Shanghai Municipality, China, 201508
- Rekrutierung
- Jinshan Hospital, Fudan University
-
Kontakt:
- ERSONG WANG
- Telefonnummer: wersong@aliyun +8618930815670
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300350
- Rekrutierung
- Tianjin Huanhu Hospital
-
Kontakt:
- JIE ZUO
- Telefonnummer: +8618920195507
- E-Mail: luckywhg@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Rekrutierung
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Kontakt:
- Gao Chen
- Telefonnummer: +8613738194475
- E-Mail: d-chengao@zju.edu.cn
-
Jinhua, Zhejiang, China, 321000
- Rekrutierung
- Jinhua Municipal Central Hospital / Jinhua Hospital Affiliated to Zhejiang University School of Medicine
-
Kontakt:
- MINFENG TONG
- Telefonnummer: +8613646694178
- E-Mail: Tmfhyj@sina.com
-
Wenzhou, Zhejiang, China, 325000
- Rekrutierung
- The First Affiliated Hospital of Wenzhou Medical University
-
Kontakt:
- QUN LI
- Telefonnummer: +8615858002900
- E-Mail: garylina@126.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Participants must meet all of the following inclusion criteria:
- Age ≥18 years at randomization；
- Diagnosed with brainstem hemorrhage via imaging (CT, CTA, etc.)；
- Hematoma volume ≥3 mL；
- Glasgow Coma Scale (GCS) score of 3-12；
- Available for surgery within 48 hours after onset；
- Modified Rankin Scale (mRS) score ≤ 1 prior to this hemorrhage；
- Informed consent obtained in accordance with national laws, regulations, and applicable ethics committee requirements.
Patients will be excluded if they meet any of the following criteria:
- Hematoma involving other regions such as the supratentorial compartment, basal ganglia, thalamus, midbrain, or ventricles.
- Radiologically confirmed cerebral vascular abnormalities including ruptured aneurysms, arteriovenous malformations (AVMs), or Moyamoya disease; hemorrhagic transformation of ischemic infarcts; or recent (within 1 year) recurrence of intracerebral hemorrhage；
- Any irreversible coagulation disorder or known coagulopathy; platelet count <100,000/µL; INR >1.4; or use of anticoagulant medication within 7 days before the current hemorrhage；
- Current or probable pregnancy；
- Patients with concurrent severe illness likely to influence outcome assessment；
- Difficulty in follow-up or poor compliance due to any cause.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Robot-assisted minimally invasive puncture and aspiration surgery
The intervention group will receive robot-assisted stereotactic puncture for brainstem hemorrhage |
Positioning and surgical operation will be performed according to the robot navigation system protocols. Preoperative imaging data will be used for precise surgical planning, including the construction of a three-dimensional (3D) preoperative visualization model. The 3D reconstruction and CT data will be imported into the AI robot-assisted stereotactic system, which, after mapping to the patient's skull, automatically designs the surgical target, calculates coordinate values, plans the puncture trajectory, and determines the cranial entry point. Different surgical approaches will be selected based on the location and shape of the hematoma, and individualized parameters, including puncture direction and trajectory length, will be generated for each patient. During the procedure, the robot will assist with stereotactic puncture, while the patient's heart rate and blood pressure are closely monitored.
Andere Namen:
According to the "Chinese Neurosurgical Expert Consensus on the Diagnosis and Treatment of Primary Brainstem Hemorrhage", conventional medical treatment includes oxygen therapy, specialized nursing care, blood pressure control (maintaining BP at ≤140/90 mmHg), sedation, intracranial pressure reduction, arousal promotion, gastric protection, maintenance of internal homeostasis, infection prevention, neuro-nutrition, brain function support, nutritional support, and overall systemic management; For comatose patients, ensure a patent airway, provide nebulization and sputum clearance, prevent respiratory depression, and improve respiratory function. Closely monitor the patient's condition and provide active symptomatic treatment as needed. Regular cranial CT scans are performed to evaluate intracranial status, and in cases of ventricular hemorrhage or obstructive hydrocephalus, lateral ventricular puncture and drainage may be performed.
Andere Namen:
|
|
Aktiver Komparator: Standard medical management
The control group will undergo conventional medical conservative management. |
According to the "Chinese Neurosurgical Expert Consensus on the Diagnosis and Treatment of Primary Brainstem Hemorrhage", conventional medical treatment includes oxygen therapy, specialized nursing care, blood pressure control (maintaining BP at ≤140/90 mmHg), sedation, intracranial pressure reduction, arousal promotion, gastric protection, maintenance of internal homeostasis, infection prevention, neuro-nutrition, brain function support, nutritional support, and overall systemic management; For comatose patients, ensure a patent airway, provide nebulization and sputum clearance, prevent respiratory depression, and improve respiratory function. Closely monitor the patient's condition and provide active symptomatic treatment as needed. Regular cranial CT scans are performed to evaluate intracranial status, and in cases of ventricular hemorrhage or obstructive hydrocephalus, lateral ventricular puncture and drainage may be performed.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Survival rate
Zeitfenster: 60 days
|
60 days survival rate after follow-up |
60 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ordinal shift in mRS scores at 60 days and 6 months
Zeitfenster: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Favorable functional outcome at 60 days and 6 months (mRS 0-1)
Zeitfenster: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Functional independence at 60 days and 6 months (mRS 0-2)
Zeitfenster: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Health-related quality of life (HRQoL) at 60 days and 6 months, assessed by the EQ-5D-5L questionnaire
Zeitfenster: 60 days and 6 months
|
Health-related quality of life (HRQoL) at 60 days and 6 months, assessed by the EQ-5D-5L questionnaire |
60 days and 6 months
|
|
Utility-weighted mRS at 60 days and 6 months
Zeitfenster: 60 days and 6 months
|
The modified Rankin Scale (mRS) is a standardized tool used to assess the neurological recovery status of stroke patients. The scale is divided into seven levels, ranging from 0 to 6. Higher scores indicate more severe patient conditions. |
60 days and 6 months
|
|
Cognitive function at 60 days and 6 months
Zeitfenster: 60 days and 6 months
|
Cognitive function at 60 days and 6 months |
60 days and 6 months
|
|
Total length of hospital stay
Zeitfenster: 60 days
|
Total length of hospital stay |
60 days
|
|
Costs during hospitalization
Zeitfenster: 60 days
|
Costs during hospitalization |
60 days
|
|
ICU length of stay
Zeitfenster: 60 days
|
ICU length of stay |
60 days
|
|
Brainstem hematoma clearance rate on postoperative days 1, 3, and 7
Zeitfenster: 1, 3, and 7 days
|
The change in hematoma volume compared to the preoperative CT scan was assessed 1, 3, and 7 days postoperatively. |
1, 3, and 7 days
|
|
Incidence of related complications within 14 days, including pneumonia, aphasia, seizures, and lower-extremity deep vein thrombosis
Zeitfenster: 14 days
|
Incidence of related complications within 14 days, including pneumonia, aphasia, seizures, and lower-extremity deep vein thrombosis |
14 days
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Yanbing Yu, M.D., China-Japan Friendship Hospital
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 01084205031
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The study has not yet begun; we will decide once recruitment starts.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .